Within weeks, the UK could start to roll out 30 million doses of a new vaccine against the CCP virus, speeding up the country’s inoculation programme because it only requires one dose to be effective. Both the Oxford/AstraZeneca and the Pfizer/BioNTech vaccines already being rolled out in the UK need two shots given weeks apart and provide relatively lower degrees of protection between first and second doses. In November the one-shot vaccine developed by U.S. company Janssen, part of pharmaceutical giant Johnson & Johnson, began to undergo a phase of clinical trials in the UK involving 6,000 volunteers across the country. It is still in larger-scale multi-country phase three trials but, according to the company, could be submitted for emergency-use approval as early as next month. The Janssen vaccine is “highly likely to work” according to Sir John Bell, regius professor of medicine at the University of Oxford and UK Vaccine …